Revenue
Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Reimbursement Of Commercialization Related Expenses | $150.80M | $169.00M | $196.10M | $159.20M | $194.00M | $182.60M | $193.50M | $184.10M |
| Reimbursement For Manufacturing Of Commercial Supplies | $157.30M | $175.10M | $169.70M | $165.00M | $161.50M | $161.50M | $154.40M | $154.30M |
| Other products | — | — | — | — | — | $800.00K | — | $31.30M |
| (Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net | -$9.10M | -$7.80M | -$11.30M | -$15.50M | -$18.00M | -$23.50M | -$12.50M | -$16.70M |
| Lynozyfic | — | — | — | — | — | — | — | $11.20M |
| Libtayo | $297.40M | $288.60M | $366.90M | $285.10M | $376.50M | — | — | — |
| Regeneron's share of profits | $988.30M | $1.09B | $1.04B | $1.02B | $1.28B | — | — | — |
| Total | $3.55B | $3.72B | $3.79B | $3.03B | $3.68B | $3.75B | $3.88B | $3.61B |
Segments
ProductView metric
Collaboration revenueView metric
Product And Service OtherView metric
LibtayoView metric
LynozyficView metric
Other productsView metric
Regeneron's share of profitsView metric
Reimbursement For Manufacturing Of Commercial SuppliesView metric
(Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, netView metric
Reimbursement Of Commercialization Related ExpensesView metric